ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?

Core Viewpoint - ANI Pharmaceuticals is expected to report its first-quarter 2024 results on May 10, with a focus on the sales performance of its core business segments: rare disease and generic business [1] Revenue Performance - The Zacks Consensus Estimate for ANI Pharmaceuticals' earnings per share is 98 cents, while total revenues are estimated at $125 million [1] - Revenue growth in the first quarter is anticipated to be driven by the uptake of rare disease products, particularly Cortrophin Gel, which has seen an increase in both new and repeat prescribers [2][3] - The Zacks Consensus Estimate for revenues from the rare disease business is $37.7 million, while revenues from the generic business and established branded products are estimated at $67.8 million and $19.5 million, respectively [3] Operating Expenses - Total operating expenses are expected to rise year over year due to increased selling, general and administrative expenses, as well as higher research and development costs associated with ongoing and new projects [4] Earnings Surprise History - ANI Pharmaceuticals has consistently surpassed earnings estimates in the past four quarters, with an average surprise of 109.06% [5] - Year-to-date, the company's shares have increased by 22%, contrasting with a 5.7% decline in the industry [5] Earnings Prediction - The company's earnings model indicates a likely earnings beat, supported by a positive Earnings ESP of +9.74% and a Zacks Rank of 2 (Buy) [6]